ONCOLOGÍA MÉDICA

ARTÍCULOS

JCR : Factor de impacto ; Cuartil ; Decil ; Posición ; Categoría

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 2021 ;11(11):2796-811 [PubMed]
JCR : 38,272; Q1 ; D1 ; 9/245 ; ONCOLOGY

Aguilera Buenosvinos I, Fernández Lázaro CI, Romanos Nanclares A, Gea A, Sánchez Bayona R, Martín Moreno JM, et al. Dairy Consumption and Incidence of Breast Cancer in the ‘Seguimiento Universidad de Navarra’ (SUN) Project. Nutrients. 2021;13(2):687 [doi]
JCR : 6,706 ; Q1 ; D2 ; 15/90 ; NUTRITION & DIETETICS

Álvarez Manceñido F, Jiménez Fonseca P, Carmona Bayonas A, Arrazubi V, Hernández R, Cano JM, et al. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021;24(4):926-36 [PubMed]
JCR : 7,708 ; Q1 ; D2 ; 49/245 ; ONCOLOGY

Amador M, Matías Guiu X, Sancho Pardo G, Contreras Martinez J, De la Torre Montero JC, Peñuelas Saiz A, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021;6(3):100157 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208-217 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(5):665-677 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Aparicio J, García del Muro X, Maroto P, Terrasa J, Castellano D, Bastús R, et al. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clin Transl Oncol. 2021;23(1):58-64 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Aragoneses Fenoll L, Montes Casado M, Ojeda G, García Paredes L, Arimura Y, Yagi J, et al. Role of endocytosis and trans-endocytosis in ICOS costimulator-induced downmodulation of the ICOS Ligand. J Leukoc Biol. 2021;110(5):867-884 [PubMed]
JCR : 6,011 ; Q2 ; D3 ; 23/78 ; HEMATOLOGY

Araújo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, et al. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. J Geriatr Oncol. 2021;12(5):820-826 [PubMed]
JCR : 3,929; Q3 ; D6 ; 29/54 ; GERIATRICS & GERONTOLOGY

Arriola E, Trigo JM, Sánchez Gastaldo A, Navarro A, Pérez C, Crama L, et al. Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis. JTO Clin Res Rep. 2021;3(1):100266 [PubMed]
JCR : – –

Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, et al. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers (Basel). 2021;13(15):3776 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

Baena J, Modrego A, Zeaiter A, Kahatt C, Alfaro V, Jiménez Aguilar E, et al. Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncol. 2021;17(18):2279-2289 [PubMed]
JCR : 3,674 ; Q3 ; D7 ; 149/245 ; ONCOLOGY

Bai Y, Cole K, Martínez Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, et al. An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. Clin Cancer Res. 2021;27(20):5557-5565 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Bamias A, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, et al. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open. 2021;6(3):100152 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148-1156 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Baudin E, Caplin M, García Carbonero R, Fazio N, Ferolla P, Filosso PL, et al.; ESMO Guidelines Committee. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(4):439-451 [PubMed] . Erratum in: Ann Oncol. 2021;32(11):1453-5 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Bazán Peregrino M, García Carbonero R, Laquente B, Álvarez R, Mato Berciano A, Giménez Alejandre M, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021;9(11):e003254 [PubMed]
JCR : 12,487 ; Q1 ; D2 ; 25/245 ; ONCOLOGY

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, et al. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. Eur Urol Focus. 2021 Sep;7(5):1084-91 [PubMed]
JCR : 5,952 ; Q1 ; D2 ; 16/90 ; UROLOGY & NEPHROLOGY

Bellmunt J, Esteban E, Del Muro XG, Sepúlveda JM, Maroto P, Gallardo E, et al. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. Eur Urol Oncol. 2021 Jun;4(3):502-5 [PubMed]
JCR : 8,208 ; Q1 ; D1 ; 9/90 ; UROLOGY & NEPHROLOGY

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al.; IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525-537 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, et al.; International Germ Cell Cancer Classification Update Consortium. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021 May 10;39(14):1553-1562 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY

Brasó Maristany F, Paré L, Chic N, Martínez Sáez O, Pascual T, Mallafré Larrosa M, et al. Gene expression profiles of breast cancer metastasis according to organ site. Mol Oncol. 2021 May 29 [PubMed]
JCR : 7,449 ; Q1 ; D3 ; 51/245 ; ONCOLOGY

Capdevila J, Fazio N, López C, Teulé A, Valle JW, Tafuto S, et al. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). J Clin Oncol. 2021 Jul 10;39(20):2304-2312 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY

Carretero González A, Otero I, Lora D, Carril Ajuria L, Castellano D, De Velasco G. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology. 2021 Feb 23;10(1):1878599 [PubMed]
JCR : 7,723 ; Q1 ; D2 ; 48/245 ; ONCOLOGY

Carril Ajuria L, Colomba E, Cerbone L, Romero Ferreiro C, Crouzet L, Laguerre B, et al. Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. Eur J Cancer. 2021 Jul;151:106-114 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Carril Ajuria L, Lora D, Carretero González A, Martín Soberón M, Rioja Viera P, Castellano D, et al. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy. Clin Genitourin Cancer. 2021 Apr;19(2):95-102 [PubMed]
JCR : 3,121 ; Q2 ; D5 ; 38/90 ; UROLOGY & NEPHROLOGY

Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, et al. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep. 2021 Sep 25;2(10):100225 [PubMed]
JCR : – –

Chic N, Schettini F, Brasó Maristany F, Sanfeliu E, Adamo B, Vidal M, et al. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine. 2021 Jun 20;69:103451 [PubMed]
JCR : 11,205 ; Q1 ; D2 ; 14/139 ; MEDICINE, RESEARCH & EXPERIMENTAL

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, et al. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-2015 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY

Clement PMJ, Dirven L, Eoli M, Sepúlveda Sánchez JM, Walenkamp AME, Frenel JS, et al. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Eur J Cancer. 2021 Apr;147:1-12 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Coleman RL, Lorusso D, Gennigens C, González Martín A, Randall L, Cibula D, et al.; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609-619 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Compte M, Harwood SL, Erce Llamazares A, Tapia Galisteo A, Romero E, Ferrer I, et al. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity. Clin Cancer Res. 2021 Jun 1;27(11):3167-3177 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Cotait Maluf FC, Pereira FMT, Serrano Uson PL Jr, Bastos DA, Rodrigues da Rosa DA, Wiermann EG, et al. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:550-558 [PubMed]
JCR : – –

De la Calle C, López Medrano F, Pablos JL, Lora-Tamayo J, Calle GM, Sánchez Fernández M, et al. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study. Int J Infect Dis. 2021 Apr;105:319-325 [doi]
JCR : 12,074 ; Q1 ; D2 ; 13/94 ; INFECTIOUS DISEASES

De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat. 2021 Oct;189(3):689-99 [PubMed]
JCR : 4,624 ; Q2 ; D5 ; 110/245 ; ONCOLOGY

De Velasco G, Ruiz Granados Á, Reig O, Massari F, Climent Durán MA, Verzoni E, et al. Outcomes of systemic targeted therapy in recurrent RCC Renal Cell Carcinoma treated with adjuvant sunitinib. BJU Int. 2021 Aug;128(2):254-261 [PubMed]
JCR : 5,969 ; Q1 ; D2 ; 15/90 ; UROLOGY & NEPHROLOGY

De Wit R, Wülfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, et al. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO Open. 2021;6(5):100241 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, et al. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. J Thorac Oncol. 2021 Dec;16(12):2139-43 [PubMed]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Dudani S, De Velasco G, Wells JC, Gan CL, Donskov F, Porta C, et al. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Netw Open. 2021 Jan 4;4(1):e2021869 [doi]
JCR : 13,366 ; Q1 ; D1 ; 15/172 ; MEDICINE, GENERAL & INTERNAL

Élez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, et al. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021;6(2):100048 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Esagian SM, Khaki AR, Diamantopoulos LN, Carril Ajuria L, Castellano D, De Kouchkovsky I, et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int. 2021 Aug;128(2):196-205 [PubMed]
JCR : 5,969 ; Q1 ; D2 ; 15/90 ; UROLOGY & NEPHROLOGY

Espinosa Olarte P, La Salvia A, Riesco Martinez MC, Antón Pascual B, García Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord. 2021 Sep;22(3):595-614 [PubMed]
JCR : 9,306 ; Q1 ; D1 ; 13/146 ; ENDOCRINOLOGY & METABOLISM

Esteban E, Expósito F, Crespo G, Lambea J, Pinto A, Puente J, et al. Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers (Basel). 2021;13(11):2849 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

Faivre Finn C, Spigel DR, Senan S, Langer C, Pérez BA, Özgüroğlu M, et al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 2021 Jan;151:30-38 [doi]
JCR : 6,081 ; Q1 ; D3 ; 16/65 ; RESPIRATORY SYSTEM

Faivre Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial. J Thorac Oncol. 2021 May;16(5):860-867 [doi]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Falco A, De Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galindo H, et al.; TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer). Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice. Cancer Manag Res. 2021 Aug 26;13:6689-6703 [PubMed]
JCR : 3,602 ; Q3 ; D7 ; 154/245 ; ONCOLOGY

Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, et al. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Eur J Cancer. 2021 Jun 30;154:246-252 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Fernández Montes A, De Velasco G, Aguín S, Farriols C, Guirado Risueño M, Jerviz Guía VG, et al. Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice. Curr Treat Options Oncol. 2021 Feb 26;22(3):26 [PubMed]
JCR : 5,080 ; Q2 ; D4 ; 91/245 ; ONCOLOGY

Fernández Ruiz M, López Medrano F, Pérez-Jacoiste Asín MA, Maestro de la Calle G, Bueno H, Caro-Teller JM, et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. J Med Virol. 2021;93(2):831-842 [doi]
JCR : 20,693 ; Q1 ; D1 ; 2/37 ; VIROLOGY

Figueiredo J, Mercadillo F, Melo S, Barroso A, Gonçalves M, Díaz Tasende J, et al. Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden. Cancers (Basel). 2021;13(17):4359 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

Fankhauser CD, Tran B, Pedregal M, Ruiz Morales JM, González Billalabeitia E, Patrikidou A, et al. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus. 2021 Sep;7(5):1130-6 [PubMed]
JCR : 5,952 ; Q1 ; D2 ; 16/90 ; UROLOGY & NEPHROLOGY

Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959-69 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021 Feb;10(4):1212-1221 [PubMed]
JCR : 4,711 ; Q2 ; D5 ; 106/245 ; ONCOLOGY

Garassino MC, Paz-Ares L, Hui R, Faivre Finn C, Spira A, Planchard D, et al. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol. 2021;17(10):1165-84 [PubMed]
JCR : 3,674 ; Q3 ; D7 ; 149/245 ; ONCOLOGY

García Alfonso P, Díaz Rubio E, Abad A, Carrato A, Massutí B, Ortiz Morales MJ, et al.; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs Aging. 2021 Mar;38(3):219-231 [doi]
JCR : 4,271 ; Q2 ; D5 ; 106/245; ONCOLOGY

García Carbonero R, Matute Teresa F, Mercader Cidoncha E, Mitjavila Casanovas M, Robledo M, Tena I, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23(10):1995-2019 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch Barrera J, et al. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 2021 Sep;10(17):5878-88 [PubMed]
JCR : 4,711 ; Q2 ; D5 ; 106/245 ; ONCOLOGY

Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, et al. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416 [PubMed]
JCR : 5,485 ; Q2 ; D4 ; 80/245 ; ONCOLOGY

Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, et al. How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. J Clin Med. 2021 Apr 1;10(7):1412 [PubMed]
JCR : 4,964 ; Q2 ; D4 ; 54/172 ; MEDICINE, GENERAL & INTERNAL

Giannetta E, La Salvia A, Rizza L, Muscogiuri G, Campione S, Pozza C, et al. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? Front Endocrinol (Lausanne). 2021 Jul 22;12:672499 [PubMed]
JCR : 6,055 ; Q1 ; D3 ; 33/146 ; ENDOCRINOLOGY & METABOLISM

Gil Gil M, Alba E, Gavilá J, De la Haba Rodríguez J, Ciruelos E, Tolosa P, et al. The role of CDK4/6 inhibitors in early breast cancer. Breast. 2021 Aug;58:160-169 [PubMed]
JCR : 4,254 ; Q1 ; D3 ; 20/85 ; OBSTETRICS & GYNECOLOGY

Gil Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, et al. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol. 2021 Jul 9;11:645026 [PubMed]
JCR : 5,738 ; Q2 ; D4 ; 78/245 ; ONCOLOGY

Giuppi M, La Salvia A, Evangelista J, Ghidini M. The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. Biology (Basel). 2021 Feb 12;10(2):146 [doi]
JCR : 5,168 ; Q1 ; D3 ; 21/94 ; BIOLOGY

Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021 Apr;186(2):417-428 [PubMed]
JCR : 4,624 ; Q2 ; D5 ; 110/245 ; ONCOLOGY

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al.; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Goldman JW, Paz-Ares L. Combination treatment options for small-cell lung cancer – Authors’ reply. Lancet Oncol. 2021;22(3):e84 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Gómez España MA, Montes AF, García Carbonero R, Mercadé TM, Maurel J, Martín AM, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol. 2021;23(5):988-1000 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

González Cao M, Mayo de las Casas C, Oramas J, Berciano Guerrero MA, De la Cruz L, Cerezuela P, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021 Dec 1;12(1):7008 [PubMed]
JCR : 17,694 ; Q1 ; D1 ; 6/73 ; MULTIDISCIPLINARY SCIENCES

González del Alba A, Méndez Vidal MJ, Vázquez S, Castro E, Climent MA, Gallardo E, et al. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol. 2021;23(5):969-979 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, et al. Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors. Eur Urol Oncol. 2021;4(1):102-11 [PubMed]
JCR : 8,208 ; Q1 ; D1 ; 9/90 ; UROLOGY & NEPHROLOGY

Grande E, Rodríguez Antona C, López C, Alonso Gordoa T, Benavent M, Capdevila J, et al. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. Oncologist. 2021 Nov;26(11):941-9 [PubMed]
JCR : 5,837 ; Q2 ; D4 ; 76/245 ; ONCOLOGY

Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, et al. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23 [doi]
JCR : 10,169 ; Q1 ; D2 ; 30/245 ; ONCOLOGY

Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, et al. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer. J Thorac Oncol. 2021;16(2):289-98 [PubMed]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Hirsch L, Martínez Chanza N, Farah S, Xie W, Flippot R, Braun DA, et al. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 1;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. Erratum in: JAMA Oncol. 2021 Dec 1;7(12):1904 [PubMed]
JCR : 33,016 ; Q1 ; D1 ; 10/245 ; ONCOLOGY

Hotta K, Nishio M, Saito H, Okamoto I, Nakahara Y, Hayashi H, et al. First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. Int J Clin Oncol. 2021;26(6):1073-1082 [PubMed]
JCR : 3,850 ; Q3 ; D6 ; 140/245 ; ONCOLOGY

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, et al. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol. 2021;17(2):137-49 [PubMed]
JCR : 3,674 ; Q3 ; D7 ; 149/245 ; ONCOLOGY

Jiménez Fonseca P, Carmona Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernández R, et al. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer. 2021;24(2):445-56 [PubMed]
JCR : 7,708 ; Q1 ; D2 ; 49/245 ; ONCOLOGY

Jiménez Fonseca P, Carmona Bayonas A, Martínez Torrón A, Alsina M, Custodio A, Serra O, et al.; AGAMENON-SEOM study group. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672 [PubMed]
JCR : 5,485 ; Q2 ; D4 ; 80/245 ; ONCOLOGY

Kahan Z, Gil Gil M, Ruiz Borrego M, Carrasco E, Ciruelos E, Muñoz M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Eur J Cancer. 2021 Aug 20;156:70-82 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, et al. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 Jun;4(3):464-72 [doi]
JCR : 8,208 ; Q1 ; D1 ; 9/90 ; UROLOGY & NEPHROLOGY

La Salvia A, Espinosa Olarte P, Riesco Martinez MDC, Antón Pascual B, García Carbonero R. Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms? Cancers (Basel). 2021;13(7):1701 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, et al. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry. 2021 May 19;109:152244 [PubMed]
JCR : 7,211 ; Q1 ; D2 ; 26/142 ; PSCHIATRY

Lamarca A, Santos Laso A, Utpatel K, La Casta A, Stock S, Forner A, et al. Reply to «Does multiple intrahepatic cholangiocarcinoma worsen prognosis as «M1″ stage?»; multiple primaries vs liver metastases. Hepatology. 2021 Feb 7 [doi]
JCR : 17,298 ; Q1 ; D1 ; 6/93 ; GASTROENTEROLOGY & HEPATOLOGY

Lamarca A, Santos Laso A, Utpatel K, La Casta A, Stock S, Forner A, et al. Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation. Hepatology. 2021 Oct;74(4):2319-2321 [PubMed]
JCR : 17,298 ; Q1 ; D1 ; 6/93 ; GASTROENTEROLOGY & HEPATOLOGY

Lamarca A, Santos Laso A, Utpatel K, La Casta A, Stock S, et al.; European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology. 2021;73(6):2311-25 [PubMed]
JCR : 17,298 ; Q1 ; D1 ; 6/93 ; GASTROENTEROLOGY & HEPATOLOGY

Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2021 Feb;16(2):205-215 [doi]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

López Medrano F, Pérez-Jacoiste Asín MA, Fernández Ruiz M, Carretero O, Lalueza A, Maestro de la Calle G, et al. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study. Int J Infect Dis. 2021 Apr;105:487-494 [doi]
JCR : 12,074 ; Q1 ; D2 ; 13/94 ; INFECTIOUS DISEASES

Lorente D, Llacer C, Lozano R, De Velasco G, Romero Laorden N, Rodrigo M, et al. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. Eur Urol. 2021 Nov;80(5):641-9 [PubMed]
JCR : 24,267 ; Q1 ; D1 ; 2/90 ; UROLOGY & NEPHROLOGY

Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M, et al. SEOM clinical guideline for management of adult medulloblastoma (2020). Clin Transl Oncol. 2021;23(5):940-947 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, et al. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. J Natl Cancer Inst. 2021;113(4):443-52 [PubMed]
JCR : 11,816 ; Q1 ; D2 ; 28/245 ; ONCOLOGY

Majem M, Cobo M, Isla D, Márquez Medina D, Rodríguez Abreu D, Casal Rubio J, et al. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. J Clin Med. 2021 Mar 26;10(7):1365 [doi]
JCR : 4,964 ; Q2 ; D4 ; 54/172 ; MEDICINE, GENERAL & INTERNAL

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, et al. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021 Oct 1 [PubMed]
JCR : 5,969 ; Q1 ; D2 ; 15/90 ; UROLOGY & NEPHROLOGY

Maluf FC, Pereira FMT, Serrano Uson PL Jr, Bastos DA, Rodrigues da Rosa DA, Wiermann EG, et al. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:550-558 [doi]
JCR : – –

Marrugal Á, Ferrer I, Gómez Sánchez D, Quintanal Villalonga Á, Pastor MD, Ojeda L, et al. Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma. Int J Mol Sci. 2021 Mar 3;22(5):2538 [doi]
JCR : 6,208 ; Q1 ; D3 ; 69/296 ; BIOCHEMISTRY & MOLECULAR BIOLOGY

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2021;32(4):488-99 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Martín Soberón MC, Ruiz S, De Velasco G, Yarza R, Carretero A, Castellano D, et al. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF^V600E mutation treated with dabrafenib-trametinib: a case report. J Med Case Rep. 2021 Mar 2;15(1):109 [doi]
JCR : – –

Martínez Sáez O, Pascual T, Brasó Maristany F, Chic N, González Farré B, Sanfeliu E, et al. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. NPJ Breast Cancer. 2021 Feb 3;7(1):8 [doi]
JCR : 7,519 ; Q1 ; D3 ; 50/245 ; ONCOLOGY

Martínez Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, et al. Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. Clin Transl Oncol. 2021;23(8):1666-1677 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

McDermott DF, Lee JL, Ziobro M, Suárez C, Langiewicz P, Matveev VB, et al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021 Mar 20;39(9):1029-1039 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY

Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021 Mar;9(3):e002068 [PubMed]
JCR : 12,487 ; Q1 ; D2 ; 25/245 ; ONCOLOGY

Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, et al. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. J Urol. 2021 Aug;206(2):240-251 [PubMed]
JCR : 7,600 ; Q1 ; D2 ; 10/90 ; UROLOGY & NEPHROLOGY

Mesia R, Iglesias L, Lambea J, Martínez Trufero J, Soria A, Taberna M, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol. 2021;23(5):913-921 [PubMed]. Erratum in: Clin Transl Oncol. 2021;23(5):1001 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, et al. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer. 2021 Jul;151:211-220 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, et al.; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245-55 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Mouron S, Manso L, Caleiras E, Rodríguez Peralto JL, Rueda OM, Caldas C, et al. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Res. 2021 Feb 12;23(1):21 [PubMed]
JCR : 8,408 ; Q1 ; D2 ; 43/245 ; ONCOLOGY

Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, et al. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2021;27(19):5258-71 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Navarro S, Cuatrecasas M, Hernández Losa J, Landolfi S, Musulén E, Ramón y Cajal S, et al. Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica. Rev Esp Patol. 2021;54(1):41-54 [PubMed]
JCR : – –

Nenclares P, Gunn L, Soliman H, Bover M, Trinh A, Leslie I, et al. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer. 2021 Jun;9(6):e002718 [PubMed]
JCR : 12,487 ; Q1 ; D2 ; 25/245 ; ONCOLOGY

Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, et al. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Glob Oncol. 2021 Feb;7:162-172 [doi]
JCR : – –

Ortega Franco A, Ackermann C, Paz-Ares L, Califano R. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO Open. 2021;6(1):100003 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, et al. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Nov 20;39(33):3725-36 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY

Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, et al. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Front Oncol. 2021 Apr 23;11:638482 [PubMed]
JCR : 5,738 ; Q2 ; D4 ; 78/245 ; ONCOLOGY

Paz-Ares L. Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC. J Thorac Oncol. 2021 Apr;16(4):e24 [PubMed]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, et al. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open. 2021;6(3):100113 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2021 Oct 12:S1556-0864(21)03207-X [PubMed]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Pérez Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, et al. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open. 2021;6(4):100212 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, et al. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112 [PubMed]
JCR : 5,738 ; Q2 ; D4 ; 78/245 ; ONCOLOGY

Pinato DJ, Scotti L, Gennari A, Colomba Blameble E, Dolly S, Loizidou A, et al. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer. 2021 Jun;150:190-202 [PubMed]
JCR : 10,002; Q1 ; D2 ; 31/245 ; ONCOLOGY

Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, et al.; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021;22(12):1669-80 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Ponce Aix S, Novello S, Garon EB, Nakagawa K, Nadal E, Moro-Sibilot D, et al.; RELAY investigators. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. Cancer Treat Res Commun. 2021;27:100378 [PubMed]
JCR : – –

Portigliatti Pomeri A, La Salvia A, Carletto S, Oliva F, Ostacoli L. EMDR in Cancer Patients: A Systematic Review. Front Psychol. 2021 Jan 18;11:590204 [doi]
JCR : 4,232 ; Q1 ; D3 ; 35/147 ; PSYCHOLOGY, MULTIDISCIPLINARY

Powell SF, Rodríguez Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, et al. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407. J Thorac Oncol. 2021 Nov;16(11):1883-92 [PubMed]
JCR : 20,121; Q1 ; D1 ; 13/245 ; ONCOLOGY

Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511-9 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021 Jul;595(7867):432-437 [PubMed]
JCR : 69,504; Q1 ; D1 ; 1/73 ; MULTIDISCIPLINARY SCIENCES

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135 [doi]
JCR : 176,079 ; Q1 ; D1 ; 2/172 ; MEDICINE, GENERAL & INTERNAL

Prieto García E, Díaz García CV, Agudo López A, Pardo Marqués V, García Consuegra I, Asensio Peña S, et al. Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines. 2021 Mar 31;9(4):364 [doi]
JCR : 4,757 ; Q2 ; D4 ; 86/279 ; PHARMACOLOGY & PHARMACY

Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, et al. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11(5):101 [PubMed]
JCR : 9,812 ; Q1 ; D2 ; 34/245 ; ONCOLOGY

Pujol JL, Vansteenkiste J, Paz-Ares Rodríguez L, Gregorc V, Mazieres J, Awad M, et al. Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. JTO Clin Res Rep. 2021 Sep 25;2(11):100234 [PubMed]
JCR : – –

Ramos Paradas J, Hernández Prieto S, Lora D, Sánchez E, Rosado A, Caniego Casas T, et al. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB² harmonization project comparing three NGS panels. J Immunother Cancer. 2021 May;9(5):e001904 [PubMed]
JCR : 12,487 ; Q1 ; D2 ; 25/245 ; ONCOLOGY

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. . First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. ;6(5):100273 [PubMed]. Erratum in ESMO Open. 2021;6(6):100345 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Redondo A, Guerra E, Manso L, Martin Lorente C, Martínez García J, Pérez Fidalgo JA, Vet al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021;23(5):961-968 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Redondo A, Oaknin A, Rubio MJ, Barretina Ginesta MP, De Juan A, Manso L, et al. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021 May 26;14(1):72 [PubMed]
JCR : 5,506 ; Q1 ; D2 ; 5/31; REPRODUCTIVE BIOLOGY

Rey Cárdenas M, Guerrero Ramos F, Gómez de Liaño Lista A, Carretero González A, Bote H, Herrera Juárez M, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat Rev. 2021 Feb;93:102142 [doi]
JCR : 13,608 ; Q1 ; D1 ; 18/245 ; ONCOLOGY

Riudavets M, Bosch Barrera J, Cabezón Gutiérrez L, Diz Taín P, Hernández A, Alonso M, et al. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clin Transl Oncol. 2021;23(12):2560-7 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489-498 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Sánchez Bayona R, Gardeazábal I, Romanos Nanclares A, Fernández Lázaro CI, Álvarez Alvarez I, Ruiz Canela M, et al. Leisure-time physical activity, sedentary behavior, and risk of breast cancer: Results from the SUN (‘Seguimiento Universidad De Navarra’) project. Prev Med. 2021 Jul;148:106535 [PubMed]
JCR : 4,637 ; Q2 ; D4 ; 69/210 ; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Sánchez Bayona R, Sayón Orea C, Gardeazabal I, Llorca J, Gea A, Santisteban M, et al. Body Shape Trajectories And Risk Of Breast Cancer: Results From The SUN (‘Seguimiento Universidad De Navarra’) Project. Public Health Nutr. 2021;24(3):467-75 [PubMed]
JCR : 4,539; Q2 ; D4 ; 73/210 ; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Santos M, Lanillos J, Roldán Romero JM, Caleiras E, Montero Conde C, Cascón A, et al. Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Genet Med. 2021 Apr;23(4):698-704 [doi]
JCR : 8,864 ; Q1 ; D1 ; 13/175 ; GENETICS & HEREDITY

Sastre J, García Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, et al.; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and ❤ baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO Open. 2021;6(2):100062 [PubMed]
JCR : 6,883 ; Q1 ; D3 ; 52/245 ; ONCOLOGY

Segura Collar B, Garranzo Asensio M, Herranz B, Hernández SanMiguel E, Cejalvo T, Casas BS, et al. Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas. Cancer Res. 2021 Apr 15;81(8):2142-2156. [PubMed]
JCR : 13,312 ; Q1 ; D1 ; 20/245 ; ONCOLOGY

Sepúlveda Sánchez JM, Pérez Núñez A. The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: A valuable tool for clinicians. Ann Oncol.  2021;32(2):139-41 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Sereno M, Jiménez Gordo AM, Baena Espinar J, Aguado C, Mielgo X, Pertejo A, et al. A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis. Cancers (Basel). 2021;13(16):4205 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

Soldevilla B, López López A, Lens Pardo A, Carretero Puche C, López Gonzálvez A, La Salvia A, et al. Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers (Basel). 2021;13(11):2634 [PubMed]
JCR : 6,575 ; Q1 ; D3 ; 60/245 ; ONCOLOGY

Sopeña Sutil R, Silva Ruiz J, García Gómez B, Romero Otero J, García González L, Duarte Ojeda JM, et al. Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis. Oncol Res Treat. 2021;44(4):154-163 [PubMed]
JCR : 2,844 ; Q4 ; D8 ; 191/245; ONCOLOGY

Sotelo M, Alonso Gordoa T, Gajate P, Gallardo E, Morales Barrera R, Pérez Gracia JL, et al. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clin Transl Oncol. 2021;23(4):882-91 [PubMed]
JCR : 3,340 ; Q3 ; D7 ; 165/245 ; ONCOLOGY

Sternberg CN, Castellano D, De Bono J, Fizazi K, Tombal B, Wülfing C, et al. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Eur Urol. 2021 Oct;80(4):497-506 [PubMed]
JCR : 24,267 ; Q1 ; D1 ; 2/90 ; UROLOGY & NEPHROLOGY

Suzuki H, Castellano D, De Bono J, Sternberg CN, Fizazi K, Tombal B, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Jpn J Clin Oncol. 2021 Aug 1;51(8):1287-1297 [PubMed]
JCR : 2,925 ; Q3 ; D8 ; 183/245 ; ONCOLOGY

Szabados B, Rodríguez Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, et al. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. Eur Urol Oncol. 2021 Jun;4(3):456-463 [doi]
JCR : 8,208 ; Q1 ; D1 ; 9/90 ; UROLOGY & NEPHROLOGY

Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021;32(5):600-608 [PubMed]
JCR : 51,769 ; Q1 ; D1 ; 5/245; ONCOLOGY

Terán S, Camara Jurado M, Nuñez Sobrino JA. A Patient with an Ileocecal MiNEN and a Synchronous Squamous Non-Small-Cell Lung Cancer: Case Report and Review of the Literature. Case Rep Oncol Med. 2021 Mar 31;2021:8896254 [doi]
JCR : – –

Trilla Fuertes L, Gámez Pozo A, Maurel J, Garcia Carbonero R, Capdevila J, G-Pastrián L, et al. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. Sci Rep. 2021 Apr 1;11(1):7402 [PubMed]
JCR : 4,996 ; Q2 ; D3 ; 19/73 ; MULTIDISCIPLINARY SCIENCES

Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, et al. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clin Cancer Res. 2021;27(20):5482-91 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, et al. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021;22(10):1468-1482 [PubMed]. Eratum in: Lancet Oncol. 2021;22(11):e472 [PubMed]
JCR : 54,433 ; Q1 ; D1 ; 4/245 ; ONCOLOGY

Vidal J, Casadevall D, Bellosillo B, Pericay C, García Carbonero R, Losa F, et al. Clinical impact of pre-surgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD1402 Trial. Clin Cancer Res. 2021 ;27(10):2890-8  [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín Méndez JJ, Custodio A, et al. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology. 2021;21(1):215-23 [PubMed]
JCR : 3,977 ; Q3 ; D6 ; 47/93 ; GASTROENTEROLOGY & HEPATOLOGY

Villalvazo P, Marzal Alfaro B, García Alfonso P, Revuelta Herrero JL, Thomas F, López Tarruella S, et al. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. J Pers Med. 2021 Aug 13;11(8):792 [PubMed]
JCR : 3,508 ; Q2 ; D4 ; 41/109 ; HEALTH CARE SCIENCES & SERVICES

Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, et al. Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. J Urol. 2021;205(2):414-9 [PubMed]
JCR : 7,600 ; Q1 ; D2 ; 10/90 ; UROLOGY & NEPHROLOGY

Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, et al. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clin Genitourin Cancer. 2021 Aug;19(4):354-361 [PubMed]
JCR : 3,121 ; Q2 ; D5 ; 38/90 ; UROLOGY & NEPHROLOGY

Yap TA, Vieito M, Baldini C, Sepúlveda Sánchez JM, Kondo S, Simonelli M, et al. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6666-76 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Yarza R, Bover M, Agulló Ortuño MT, Iglesias Docampo LC. Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. J Exp Clin Cancer Res. 2021 Jun 21;40(1):202 [PubMed]
JCR : 12,658 ; Q1 ; D1 ; 24/245 ; ONCOLOGY

Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, et al. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 Feb 15;27(4):992-1002 [PubMed]
JCR : 13,801; Q1 ; D1 ; 17/245 ; ONCOLOGY

Zambrana F, Carril Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, et al.. Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. Cancer Treat Rev. 2021 Jun 1;99:102239 [PubMed]
JCR : 13,608 ; Q1 ; D1 ; 18/245 ; ONCOLOGY

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 1;7(11):1669-77 [PubMed]
JCR : 33,016 ; Q1 ; D1 ; 10/245 ; ONCOLOGY

Zugazagoitia J, Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022 Jan 5:JCO2101881 [PubMed]
JCR : 50,769 ; Q1 ; D1 ; 6/245 ; ONCOLOGY